Entrada Therapeutics TRDA
NASDAQ TRDA
$6.17 -0.18 (-2.83%)
As of: Oct 1, 2026 · 10:39 AM EDT

Entrada Therapeutics (TRDA) Liabilities and Shareholders Equity (2020 - 2026)

Updated

Entrada Therapeutics' Liabilities and Shareholders Equity came in at $298.88 million for Q2 2026, down 33.4% from $448.78 million a year earlier and down 10.9% from the prior quarter.

Analysis

Entrada Therapeutics (TRDA) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

At the end of FY2025, Entrada Therapeutics' Liabilities and Shareholders Equity was $377.38 million, down 28.3% from FY2024.

  • Liabilities and Shareholders Equity carries a five-year compound annual growth rate of 54.0% (FY2020 to FY2025).
  • Going back by year, Liabilities and Shareholders Equity was $526.32 million in FY2024 (+12.2%), $469.19 million in FY2023 (+86.1%), $252.06 million in FY2022 (-17.6%) and $305.83 million in FY2021 (+602.6%).
  • The Q2 2026 figure represents the lowest quarterly Liabilities and Shareholders Equity since Q4 2022.
  • Year-over-year, Liabilities and Shareholders Equity has declined for six consecutive quarters, with an average decline of 14.9% over the last eight quarters.
  • The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in Q4 2021 (growth of 602.6%), and the weakest in Q2 2026 (a decline of 33.4%).
  • Business Quant data shows TRDA's Liabilities and Shareholders Equity at $335.52 million (Q1 2026), $377.38 million (Q4 2025) and $412.9 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Entrada Therapeutics 247.25 Mn 247.25 Mn - 298.88 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 298.88 Mn
Mar 31, 2026 335.52 Mn
Dec 31, 2025 377.38 Mn
Sep 30, 2025 412.90 Mn
Jun 30, 2025 448.78 Mn
Mar 31, 2025 486.48 Mn
Dec 31, 2024 526.32 Mn
Sep 30, 2024 554.59 Mn
Jun 30, 2024 581.96 Mn
Mar 31, 2024 510.84 Mn
Dec 31, 2023 469.19 Mn
Sep 30, 2023 485.03 Mn
Jun 30, 2023 493.98 Mn
Mar 31, 2023 475.57 Mn
Dec 31, 2022 252.06 Mn
Sep 30, 2022 274.46 Mn
Jun 30, 2022 295.92 Mn
Mar 31, 2022 316.70 Mn
Dec 31, 2021 305.83 Mn
Sep 30, 2021 132.40 Mn
API Access

Entrada Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=TRDA&period=max&api_key=YOUR_API_KEY